Benitec Biopharma has made two key appointments to its management team. Sophie Mukadam has been named the company’s new Chief Operating Officer, while Megan Boston, currently an executive director, will take on the role of Chief Financial Officer. Both appointments are set to take effect on January 1.
Mukadam, who has been with Benitec since May 2021 as Associate Director of Program Management, will step into her new role with a base salary of $500,000. Additionally, she will be eligible for a target annual bonus of 40% of her base salary, as disclosed in a filing with the Securities and Exchange Commission. Before joining Benitec, Mukadam worked as a regulatory consultant and holds a bachelor’s degree from the University of California, Berkeley.
Meanwhile, Megan Boston will take over as CFO and will also serve as the company’s secretary. Her new role will come with an annual salary of $415,000, along with the potential for a discretionary bonus of up to 40% of that figure. In addition, Boston has been granted nonqualified stock options, giving her the right to purchase 720,000 shares at an exercise price of $12.18 per share, according to the filing. Boston will continue in her roles as the principal financial officer and principal accounting officer.